Brooklyn Historical Income Statement

BTX
 Stock
  

USD 0.65  0.01  1.56%   

Historical analysis of Brooklyn Immunotherapeuti income statement accounts such as Cost of Revenue of 9.2 M, Gross Profit of 12.2 M or Interest Expense of 314.2 K can show how well Brooklyn Immunotherapeutics performed in making a profits. Evaluating Brooklyn Immunotherapeuti income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Brooklyn Immunotherapeuti's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Brooklyn Immunotherapeuti latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Brooklyn Immunotherapeuti is a good buy for the upcoming year.
Continue to Trending Equities.
  
Refresh

Brooklyn Immunotherapeuti Net Income

(125.77 Million)

About Brooklyn Income Statement Analysis

Brooklyn Immunotherapeuti Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Brooklyn Immunotherapeuti shareholders. The income statement also shows Brooklyn investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Brooklyn Immunotherapeuti Income Statement Chart

Brooklyn Immunotherapeutics Income Statement is one of the three primary financial statements used for reporting Brooklyn's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Brooklyn Immunotherapeuti revenue and expense. Brooklyn Immunotherapeuti Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.8 M) in 2022.

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding Income Tax Expense and Interest Expense back to Net Income.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Brooklyn Immunotherapeutics minus its cost of goods sold. It is profit before Brooklyn Immunotherapeuti operating expenses, interest payments and taxes. Gross profit is also known as gross margin. Aggregate revenue Revenues less cost of revenue [CoR] directly attributable to the revenue generation activity.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Brooklyn Immunotherapeuti financial statement analysis. It represents the amount of money remaining after all of Brooklyn Immunotherapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends Income Statement Impact.

Revenues

Revenues refers to the total amount of money received by Brooklyn Immunotherapeuti for goods sold or services provided during a certain time period. It also includes all of Brooklyn Immunotherapeuti sales as well as any other increase in Brooklyn Immunotherapeutics equity.Revenues are reported on Brooklyn Immunotherapeuti income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.
Most accounts from Brooklyn Immunotherapeuti income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Brooklyn Immunotherapeuti current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.Brooklyn Immunotherapeuti Direct Expenses is fairly stable at the moment as compared to the past year. Brooklyn Immunotherapeuti reported Direct Expenses of 442,750 in 2021. Cost of Revenue is likely to rise to about 9.2 M in 2022, whereas Consolidated Income is likely to drop (125.8 M) in 2022.
 2018 2019 2021 2022 (projected)
Interest Expense389 K249 K286.35 K314.17 K
Gross Profit15.27 M12.32 M11.09 M12.18 M

Brooklyn Immunotherapeuti income statement Correlations

Brooklyn Immunotherapeuti Account Relationship Matchups

Brooklyn Immunotherapeuti income statement Accounts

201720182019202020212022 (projected)
Direct Expenses168 K302 K412 K385 K442.75 K541.54 K
Consolidated Income(1.08 M)(259 K)(2.05 M)(7.29 M)(122.55 M)(125.77 M)
Cost of Revenue7.71 M6.75 M8.07 M7.48 M8.61 M9.25 M
Earning Before Interest and Taxes EBIT(513 K)66 K(1.77 M)(7.29 M)(122.48 M)(125.7 M)
Earning Before Interest and Taxes USD(513 K)66 K(1.77 M)(7.29 M)(122.48 M)(125.7 M)
Gross Profit14.6 M14.52 M15.27 M12.32 M11.09 M12.18 M
Interest Expense576 K498 K389 K249 K286.35 K314.17 K
Net Income(1.08 M)(259 K)(2.05 M)(7.29 M)(122.55 M)(125.77 M)
Net Income Common Stock(1.09 M)(275 K)(2.06 M)(7.29 M)(122.56 M)(125.79 M)
Net Income Common Stock USD(1.09 M)(275 K)(2.06 M)(7.29 M)(122.56 M)(125.79 M)
Operating Expenses15.92 M15.06 M14.09 M7.25 M113.73 M122.71 M
Operating Income(1.4 M)203 K(1.77 M)(7.25 M)(113.73 M)(116.72 M)
Revenues22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Revenues USD22.31 M21.27 M23.34 M19.81 M17.83 M19.16 M
Selling General and Administrative Expense15.59 M14.46 M13.18 M3.3 M14.72 M14.22 M
Weighted Average Shares1.22 M1.34 M1.44 M17.59 M43.31 M46.72 M
Weighted Average Shares Diluted1.22 M1.34 M1.44 M17.59 M43.31 M46.72 M
Income Tax Expense66 K(64 K)27 K64 K57.6 K62.15 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in Brooklyn Immunotherapeuti without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module
Continue to Trending Equities. Note that the Brooklyn Immunotherapeuti information on this page should be used as a complementary analysis to other Brooklyn Immunotherapeuti's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Brooklyn Stock analysis

When running Brooklyn Immunotherapeuti price analysis, check to measure Brooklyn Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brooklyn Immunotherapeuti is operating at the current time. Most of Brooklyn Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of Brooklyn Immunotherapeuti's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Brooklyn Immunotherapeuti's price. Additionally, you may evaluate how the addition of Brooklyn Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is Brooklyn Immunotherapeuti's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Brooklyn Immunotherapeuti. If investors know Brooklyn will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Brooklyn Immunotherapeuti listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
33.7 M
Return On Assets
-0.65
Return On Equity
-17.56
The market value of Brooklyn Immunotherapeuti is measured differently than its book value, which is the value of Brooklyn that is recorded on the company's balance sheet. Investors also form their own opinion of Brooklyn Immunotherapeuti's value that differs from its market value or its book value, called intrinsic value, which is Brooklyn Immunotherapeuti's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Brooklyn Immunotherapeuti's market value can be influenced by many factors that don't directly affect Brooklyn Immunotherapeuti's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Brooklyn Immunotherapeuti's value and its price as these two are different measures arrived at by different means. Investors typically determine Brooklyn Immunotherapeuti value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Brooklyn Immunotherapeuti's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.